Skip to main content
Top
Published in: BMC Infectious Diseases 1/2012

Open Access 01-12-2012 | Research article

Soluble RAGE as a severity marker in community acquired pneumonia associated sepsis

Authors: Rodrigo M Narvaez-Rivera, Adrian Rendon, Mario C Salinas-Carmona, Adrian G Rosas-Taraco

Published in: BMC Infectious Diseases | Issue 1/2012

Login to get access

Abstract

Background

Community-acquired pneumonia (CAP) is considered the most important cause of death from infectious disease in developed countries. Severity assessment scores partially address the difficulties in identifying high-risk patients. A lack of specific and valid pathophysiologic severity markers affect early and effective sepsis therapy. HMGB-1, sRAGE and RAGE have been involved in sepsis and their potential as severity markers has been proposed. The aim of this study was to evaluate HMGB-1, RAGE and sRAGE levels in patients with CAP-associated sepsis and determine their possible association with clinical outcome.

Method

We evaluated 33 patients with CAP-associated sepsis admitted to the emergency room and followed in the medical wards. Severity assessment scores (CURB-65, PSI, APACHE II, SOFA) and serologic markers (HMGB-1, RAGE, sRAGE) were evaluated on admission.

Results

Thirty patients with a diagnosis of CAP-associated sepsis were enrolled in the study within 24 hours after admission. Fourteen (46.6%) had pandemic (H1N1) influenza A virus, 2 (6.6%) had seasonal influenza A and 14 other diagnoses. Of the patients in the study group, 16 (53.3%) had a fatal outcome. ARDS was observed in 17 (56.6%) and a total of 22 patients had severe sepsis on admission (73%). The SOFA score showed the greatest difference between surviving and non-surviving groups (P = .003) with similar results in ARDS patients (P = .005). sRAGE levels tended to be higher in non-surviving (P = .058) and ARDS patients (P = .058). Logistic regression modeling demonstrated that SOFA (P = .013) and sRAGE (P = .05) were the only variables that modified the probability of a fatal outcome.

Conclusion

The association of elevated sRAGE with a fatal outcome suggests that it may have an independent causal effect in CAP. SOFA scores were the only clinical factor with the ability to identify surviving and ARDS patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mandell LA, et al: Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007, 44 (Suppl 2): S27-72.CrossRefPubMed Mandell LA, et al: Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007, 44 (Suppl 2): S27-72.CrossRefPubMed
2.
go back to reference Epidemiologic Vigilance. 2003, DGE/SSA in Mexico 51st week Epidemiologic Vigilance. 2003, DGE/SSA in Mexico 51st week
3.
go back to reference Perez-Padilla R, et al: Pneumonia and respiratory failure from swine-origin influenza a (H1N1) in Mexico. N Engl J Med. 2009, 361 (7): 680-689. 10.1056/NEJMoa0904252.CrossRefPubMed Perez-Padilla R, et al: Pneumonia and respiratory failure from swine-origin influenza a (H1N1) in Mexico. N Engl J Med. 2009, 361 (7): 680-689. 10.1056/NEJMoa0904252.CrossRefPubMed
4.
go back to reference Martinez-Hernandez F, et al: What happened after the initial global spread of pandemic human influenza virus A (H1N1)? a population genetics approach. Virol J. 2010, 7: 196-10.1186/1743-422X-7-196.CrossRefPubMedPubMedCentral Martinez-Hernandez F, et al: What happened after the initial global spread of pandemic human influenza virus A (H1N1)? a population genetics approach. Virol J. 2010, 7: 196-10.1186/1743-422X-7-196.CrossRefPubMedPubMedCentral
5.
go back to reference Pandemic influenza: the new wave. Lancet Infect Dis. 2009, 9 (10): 583-10.1016/S1473-3099(09)70236-1. Pandemic influenza: the new wave. Lancet Infect Dis. 2009, 9 (10): 583-10.1016/S1473-3099(09)70236-1.
6.
go back to reference Dominguez-Cherit G, et al: H1N1 influenza pandemic of 2009 compared with other influenza pandemics: epidemiology, diagnosis, management, pulmonary complications, and outcomes. Curr Infect Dis Rep. 2010, 12 (3): 204-210. 10.1007/s11908-010-0097-0.CrossRefPubMed Dominguez-Cherit G, et al: H1N1 influenza pandemic of 2009 compared with other influenza pandemics: epidemiology, diagnosis, management, pulmonary complications, and outcomes. Curr Infect Dis Rep. 2010, 12 (3): 204-210. 10.1007/s11908-010-0097-0.CrossRefPubMed
7.
go back to reference Bautista E, et al: Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med. 2010, 362 (18): 1708-1719.CrossRefPubMed Bautista E, et al: Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med. 2010, 362 (18): 1708-1719.CrossRefPubMed
8.
go back to reference Kumar A, et al: Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA. 2009, 302 (17): 1872-1879. 10.1001/jama.2009.1496.CrossRefPubMed Kumar A, et al: Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA. 2009, 302 (17): 1872-1879. 10.1001/jama.2009.1496.CrossRefPubMed
9.
go back to reference Webb SA, et al: Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med. 2009, 361 (20): 1925-1934.CrossRefPubMed Webb SA, et al: Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med. 2009, 361 (20): 1925-1934.CrossRefPubMed
10.
go back to reference Rello J, et al: Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain. Crit Care. 2009, 13 (5): R148-10.1186/cc8044.CrossRefPubMedPubMedCentral Rello J, et al: Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain. Crit Care. 2009, 13 (5): R148-10.1186/cc8044.CrossRefPubMedPubMedCentral
11.
go back to reference Tang CM, Macfarlane JT: Early management of younger adults dying of community acquired pneumonia. Respir Med. 1993, 87 (4): 289-294. 10.1016/0954-6111(93)90025-U.CrossRefPubMed Tang CM, Macfarlane JT: Early management of younger adults dying of community acquired pneumonia. Respir Med. 1993, 87 (4): 289-294. 10.1016/0954-6111(93)90025-U.CrossRefPubMed
12.
go back to reference Neill AM, et al: Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax. 1996, 51 (10): 1010-1016. 10.1136/thx.51.10.1010.CrossRefPubMedPubMedCentral Neill AM, et al: Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax. 1996, 51 (10): 1010-1016. 10.1136/thx.51.10.1010.CrossRefPubMedPubMedCentral
13.
go back to reference Fine MJ, et al: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997, 336 (4): 243-250. 10.1056/NEJM199701233360402.CrossRefPubMed Fine MJ, et al: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997, 336 (4): 243-250. 10.1056/NEJM199701233360402.CrossRefPubMed
14.
go back to reference Lee RW, Lindstrom ST: A teaching hospital's experience applying the pneumonia severity index and antibiotic guidelines in the management of community-acquired pneumonia. Respirology. 2007, 12 (5): 754-758. 10.1111/j.1440-1843.2007.01121.x.CrossRefPubMed Lee RW, Lindstrom ST: A teaching hospital's experience applying the pneumonia severity index and antibiotic guidelines in the management of community-acquired pneumonia. Respirology. 2007, 12 (5): 754-758. 10.1111/j.1440-1843.2007.01121.x.CrossRefPubMed
15.
go back to reference Lim WS, et al: Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003, 58 (5): 377-382. 10.1136/thorax.58.5.377.CrossRefPubMedPubMedCentral Lim WS, et al: Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003, 58 (5): 377-382. 10.1136/thorax.58.5.377.CrossRefPubMedPubMedCentral
16.
go back to reference Ho KM: Combining sequential organ failure assessment (SOFA) score with acute physiology and chronic health evaluation (APACHE) II score to predict hospital mortality of critically ill patients. Anaesth Intensive Care. 2007, 35 (4): 515-521.PubMed Ho KM: Combining sequential organ failure assessment (SOFA) score with acute physiology and chronic health evaluation (APACHE) II score to predict hospital mortality of critically ill patients. Anaesth Intensive Care. 2007, 35 (4): 515-521.PubMed
17.
go back to reference Singanayagam A, Chalmers JD, Hill AT: Severity assessment in community-acquired pneumonia: a review. QJM. 2009, 102 (6): 379-388. 10.1093/qjmed/hcp027.CrossRefPubMed Singanayagam A, Chalmers JD, Hill AT: Severity assessment in community-acquired pneumonia: a review. QJM. 2009, 102 (6): 379-388. 10.1093/qjmed/hcp027.CrossRefPubMed
18.
go back to reference Wang H, et al: HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999, 285 (5425): 248-251. 10.1126/science.285.5425.248.CrossRefPubMed Wang H, et al: HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999, 285 (5425): 248-251. 10.1126/science.285.5425.248.CrossRefPubMed
19.
go back to reference Angus DC, et al: Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. Crit Care Med. 2007, 35 (4): 1061-1067. 10.1097/01.CCM.0000259534.68873.2A.CrossRefPubMed Angus DC, et al: Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. Crit Care Med. 2007, 35 (4): 1061-1067. 10.1097/01.CCM.0000259534.68873.2A.CrossRefPubMed
20.
go back to reference Sunden-Cullberg J, et al: Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med. 2005, 33 (3): 564-573. 10.1097/01.CCM.0000155991.88802.4D.CrossRefPubMed Sunden-Cullberg J, et al: Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med. 2005, 33 (3): 564-573. 10.1097/01.CCM.0000155991.88802.4D.CrossRefPubMed
21.
go back to reference Bierhaus A, Stern DM, Nawroth PP: RAGE in inflammation: a new therapeutic target?. Curr Opin Investig Drugs. 2006, 7 (11): 985-991.PubMed Bierhaus A, Stern DM, Nawroth PP: RAGE in inflammation: a new therapeutic target?. Curr Opin Investig Drugs. 2006, 7 (11): 985-991.PubMed
22.
go back to reference Liliensiek B, et al: Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest. 2004, 113 (11): 1641-1650.CrossRefPubMedPubMedCentral Liliensiek B, et al: Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest. 2004, 113 (11): 1641-1650.CrossRefPubMedPubMedCentral
23.
go back to reference Hudson BI, et al: Identification, classification, and expression of RAGE gene splice variants. FASEB J. 2008, 22 (5): 1572-1580.CrossRefPubMed Hudson BI, et al: Identification, classification, and expression of RAGE gene splice variants. FASEB J. 2008, 22 (5): 1572-1580.CrossRefPubMed
24.
go back to reference Bone RC, Sibbald WJ, Sprung CL: The ACCP-SCCM consensus conference on sepsis and organ failure. Chest. 1992, 101 (6): 1481-1483. 10.1378/chest.101.6.1481.CrossRefPubMed Bone RC, Sibbald WJ, Sprung CL: The ACCP-SCCM consensus conference on sepsis and organ failure. Chest. 1992, 101 (6): 1481-1483. 10.1378/chest.101.6.1481.CrossRefPubMed
25.
go back to reference Angus DC, Pereira CA, Silva E: Epidemiology of severe sepsis around the world. Endocr Metab Immune Disord Drug Targets. 2006, 6 (2): 207-212.CrossRefPubMed Angus DC, Pereira CA, Silva E: Epidemiology of severe sepsis around the world. Endocr Metab Immune Disord Drug Targets. 2006, 6 (2): 207-212.CrossRefPubMed
26.
go back to reference Marshall JC, et al: Measures, markers, and mediators: toward a staging system for clinical sepsis. A report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25-26, 2000. Crit Care Med. 2003, 31 (5): 1560-1567. 10.1097/01.CCM.0000065186.67848.3A.CrossRefPubMed Marshall JC, et al: Measures, markers, and mediators: toward a staging system for clinical sepsis. A report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25-26, 2000. Crit Care Med. 2003, 31 (5): 1560-1567. 10.1097/01.CCM.0000065186.67848.3A.CrossRefPubMed
27.
go back to reference Roch A, et al: NH2 terminal pro-brain natriuretic peptide plasma level as an early marker of prognosis and cardiac dysfunction in septic shock patients. Crit Care Med. 2005, 33 (5): 1001-1007. 10.1097/01.CCM.0000162561.82012.E9.CrossRefPubMed Roch A, et al: NH2 terminal pro-brain natriuretic peptide plasma level as an early marker of prognosis and cardiac dysfunction in septic shock patients. Crit Care Med. 2005, 33 (5): 1001-1007. 10.1097/01.CCM.0000162561.82012.E9.CrossRefPubMed
28.
go back to reference Gibot S, et al: Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Crit Care Med. 2005, 33 (4): 792-796. 10.1097/01.CCM.0000159089.16462.4A.CrossRefPubMed Gibot S, et al: Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Crit Care Med. 2005, 33 (4): 792-796. 10.1097/01.CCM.0000159089.16462.4A.CrossRefPubMed
29.
go back to reference Ewig S, Welte T: Biomarkers in the diagnosis of pneumonia in the critically ill: don't shoot the piano player. Intensive Care Med. 2008, 34 (6): 981-984. 10.1007/s00134-008-1088-6.CrossRefPubMed Ewig S, Welte T: Biomarkers in the diagnosis of pneumonia in the critically ill: don't shoot the piano player. Intensive Care Med. 2008, 34 (6): 981-984. 10.1007/s00134-008-1088-6.CrossRefPubMed
30.
go back to reference Challen K, et al: Evaluation of triage methods used to select patients with suspected pandemic influenza for hospital admission. Emerg Med J. 2011, doi:10.1136/emj.2010.104380 Challen K, et al: Evaluation of triage methods used to select patients with suspected pandemic influenza for hospital admission. Emerg Med J. 2011, doi:10.1136/emj.2010.104380
31.
go back to reference Brandao-Neto RA, et al: The role of Pneumonia scores in the emergency room in patients infected by 2009 H1N1 infection. Eur J Emerg Med. 2011, doi: 10.1097/MEJ.0b013e328349ed85 Brandao-Neto RA, et al: The role of Pneumonia scores in the emergency room in patients infected by 2009 H1N1 infection. Eur J Emerg Med. 2011, doi: 10.1097/MEJ.0b013e328349ed85
33.
go back to reference Gaini S, et al: High mobility group box-1 protein in patients with suspected community-acquired infections and sepsis: a prospective study. Crit Care. 2007, 11 (2): R32-10.1186/cc5715.CrossRefPubMedPubMedCentral Gaini S, et al: High mobility group box-1 protein in patients with suspected community-acquired infections and sepsis: a prospective study. Crit Care. 2007, 11 (2): R32-10.1186/cc5715.CrossRefPubMedPubMedCentral
34.
go back to reference Lee N, et al: Hypercytokinemia and hyperactivation of phospho-p38 mitogen-activated protein kinase in severe human influenza A virus infection. Clin Infect Dis. 2007, 45 (6): 723-731. 10.1086/520981.CrossRefPubMed Lee N, et al: Hypercytokinemia and hyperactivation of phospho-p38 mitogen-activated protein kinase in severe human influenza A virus infection. Clin Infect Dis. 2007, 45 (6): 723-731. 10.1086/520981.CrossRefPubMed
35.
go back to reference de Jong MD, et al: Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006, 12 (10): 1203-1207. 10.1038/nm1477.CrossRefPubMedPubMedCentral de Jong MD, et al: Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006, 12 (10): 1203-1207. 10.1038/nm1477.CrossRefPubMedPubMedCentral
36.
go back to reference Alleva LM, Budd AC, Clark IA: Systemic release of high mobility group box 1 protein during severe murine influenza. J Immunol. 2008, 181 (2): 1454-1459.CrossRefPubMed Alleva LM, Budd AC, Clark IA: Systemic release of high mobility group box 1 protein during severe murine influenza. J Immunol. 2008, 181 (2): 1454-1459.CrossRefPubMed
37.
go back to reference Bopp C, et al: sRAGE is elevated in septic patients and associated with patients outcome. J Surg Res. 2008, 147 (1): 79-83. 10.1016/j.jss.2007.07.014.CrossRefPubMed Bopp C, et al: sRAGE is elevated in septic patients and associated with patients outcome. J Surg Res. 2008, 147 (1): 79-83. 10.1016/j.jss.2007.07.014.CrossRefPubMed
38.
go back to reference van Zoelen MA, Achouiti A, van der Poll T: RAGE during infectious diseases. Front Biosci (Schol Ed). 2011, 3: 1119-1132.CrossRef van Zoelen MA, Achouiti A, van der Poll T: RAGE during infectious diseases. Front Biosci (Schol Ed). 2011, 3: 1119-1132.CrossRef
39.
go back to reference Yamagishi S, et al: Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism. 2006, 55 (9): 1227-1231. 10.1016/j.metabol.2006.05.007.CrossRefPubMed Yamagishi S, et al: Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism. 2006, 55 (9): 1227-1231. 10.1016/j.metabol.2006.05.007.CrossRefPubMed
Metadata
Title
Soluble RAGE as a severity marker in community acquired pneumonia associated sepsis
Authors
Rodrigo M Narvaez-Rivera
Adrian Rendon
Mario C Salinas-Carmona
Adrian G Rosas-Taraco
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2012
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-12-15

Other articles of this Issue 1/2012

BMC Infectious Diseases 1/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.